search results for 
Logo

Sales and earnings by business segment

In 2012, we expect further increases in sales and earnings in each of our business segments. The table gives an overview.

FINANCIAL TARGETS BY BUSINESS SEGMENT


  Targets 2012 Fiscal year 2011
1 Net income attributable to Fresenius Medical Care AG & Co. KGaA
2 Sales
3 EBIT
Fresenius Medical Care    
Sales ~US$14.0 bn US$12.795 bn
Net income1 ~US$1.14 bn US$1.071 bn
Fresenius Kabi    
Sales growth (organic) 4% – 6% €3,964 m2
EBIT margin 19.5% – 20.0% 20.3%
Fresenius Helios    
Sales growth (organic) 3% – 5% €2,665 m2
EBIT €310 – €320 m €270 m
Fresenius Vamed    
Sales growth 5% – 10% €737 m2
EBIT growth 5% – 10% €44 m3
Fresenius Biotech    
EBIT -€25 – -€30 m -€30 m

  Targets 2012 Fiscal year 2011
1 Net income attributable to Fresenius Medical Care AG & Co. KGaA
2 Sales
3 EBIT
Fresenius Medical Care    
Sales ~US$14.0 bn US$12.795 bn
Net income1 ~US$1.14 bn US$1.071 bn
Fresenius Kabi    
Sales growth (organic) 4% – 6% €3,964 m2
EBIT margin 19.5% – 20.0% 20.3%
Fresenius Helios    
Sales growth (organic) 3% – 5% €2,665 m2
EBIT €310 – €320 m €270 m
Fresenius Vamed    
Sales growth 5% – 10% €737 m2
EBIT growth 5% – 10% €44 m3
Fresenius Biotech    
EBIT -€25 – -€30 m -€30 m

The number of dialysis patients worldwide should rise by about 6% again in 2012, leading to continued growth in demand for dialysis products and a higher number of treatments. For 2012, Fresenius Medical Care expects sales to grow to around US$14.0 billion. This takes into account a change in U.S. GAAP in the presentation of U.S. dialysis service sales which will be shown net of the provision for bad debt. Based on the comparable 2011 sales of US$12,571 million the sales outlook represents an increase of 11% and between 13% and 15% based on constant currencies. Net income is expected to grow to around US$1.3 billion and net income1 is expected to grow to around US$1.14 billion with operating margins forecast to increase to approximately 16.9%.

Fresenius Kabi expects its positive operating performance to continue. The company projects organic sales growth of 4% to 6%. High growth potential is expected again in emerging markets. Based on this positive sales projection, further cost optimizations, especially in production, and an improved product mix, Fresenius Kabi again expects to increase earnings in 2012. Fresenius Kabi forecasts an EBIT margin of 19.5% to 20.0%, again achieving an excellent margin level.

Fresenius Helios expects a continued good performance in the hospital operations business. The company forecasts an organic sales growth of 3% to 5% in 2012. EBIT is expected to increase to between €310 million to €320 million.

Given its excellent order backlog of €845 million and long-term agreements in its service business, Fresenius Vamed has an excellent base for further growth. In 2012, Fresenius Vamed expects to achieve both sales and EBIT growth between 5% and 10%.

Fresenius Biotech is expected to further reduce its negative EBIT to about -€25 million and -€30 million.

Continue reading:
Financing

QUICKFINDER

History

Tools